Abstract
This disclosure describes the Glucose Resetter #36, a non-invasive focused ultrasound (FUS) device targeting the porta hepatis hepatic plexus to achieve 25–30% fasting glucose reduction in Type 2 diabetes patients via reversible neuromodulation, validated by NCT04502212 Phase 1 human data showing 25% glucose drop at 0.2 MPa. The wearable patch (10x10 cm, 1024-element PZT array at 1.1 MHz) delivers pulsed FUS (0.2–0.45 MPa, 1% duty cycle, ISPTA < 720 mW/cm²) with real-time PCD monitoring (TCL 0.5–1 dB safety limit) and Verilog-controlled FPGA steering (Virtex-7 SX35T) for automated plexus localization via impedance mapping. The system integrates dual LiFePO4 batteries (4h runtime), Peltier cooling (propylene glycol loop), and Bluetooth telemetry to Starlink-enabled Vortex-Cart (#33) for remote monitoring. Total prototype cost is $24,800 for n=12 pig trial capability (ApoE⁻/⁻ model, 6-week protocol: baseline → FUS → HbA1c/glucose metrics). The device weighs 4.2 kg, operates at body temperature, and requires no drugs or incisions. Scalable to human Phase 1b via existing FDA-cleared FUS predicates (e.g., Insightec Exablate). The disclosure includes complete BOM ($24.8k), Verilog FPGA code, PCD safety algorithm, pig trial protocol (n=12, $100k total), and integration with Bio-Lego NAMs (#40) for multi-indication expansion. CERN-OHL-P licensed for global diabetes
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Recommended Citation
Caldwell, Michael Victor Mr., "Glucose Resetter #36: Non-Invasive FUS Hepatic Neuromodulation Device for Type 2 Diabetes", Technical Disclosure Commons, (February 25, 2026)
https://www.tdcommons.org/dpubs_series/9390
Improvement on #36 Glucose invent.